As reported before, Zhao and colleagues, showed the capability of the synthetic non-steroidal selective ERβ agonist LY500307 to reduce melanoma lung metastasis in a murine melanoma in vivo model, by innate immunity upregulation in the metastatic niche 19. The gene discussed is ESR2; the disease is melanoma.